WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Skøyen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

G GENITO URINARY SYSTEM AND SEX HORMONES
G02 OTHER GYNECOLOGICALS

Analgesics used in dysmenorrhea, see N02B - Other analgesics and antipyretics and M01A - Antiinflammatory and antirheumatic products, non-steroids.


G02C OTHER GYNECOLOGICALS
G02CB Prolactine inhibitors

Cabergoline and bromocriptine low dose tablets are classified in this group. Cabergoline and bromocriptine tablets in higher strengths are classified in N04 - Anti-Parkinson drugs.


Lisuride tablets in high strength (0.2 mg) are classified in this group, while low strength tablets (25 mcg) are classified in N02C -Antimigraine preparations.

The DDDs are based on use as lactation inhibitors. The DDD for parenteral depot formulations of bromocriptine is equal to the DDD for oral administration, based on the assumption that the single dose parenteral treatment equals 14 days of oral treatment.


    ATC code  Name  DDD  U Adm.R Note
    G02CB03 cabergoline 0.5 mg 

List of abbreviations

Last updated: 2024-01-26